183 related articles for article (PubMed ID: 18043127)
1. Synthesis and anticancer activities of 6-amino amonafide derivatives.
Norton JT; Witschi MA; Luong L; Kawamura A; Ghosh S; Stack MS; Sim E; Avram MJ; Appella DH; Huang S
Anticancer Drugs; 2008 Jan; 19(1):23-36. PubMed ID: 18043127
[TBL] [Abstract][Full Text] [Related]
2. 5-Non-amino aromatic substituted naphthalimides as potential antitumor agents: Synthesis via Suzuki reaction, antiproliferative activity, and DNA-binding behavior.
Xie L; Cui J; Qian X; Xu Y; Liu J; Xu R
Bioorg Med Chem; 2011 Jan; 19(2):961-7. PubMed ID: 21208805
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of new amonafide analogues via coupling reaction and their cytotoxic evaluation and DNA-binding studies.
Xie L; Xu Y; Wang F; Liu J; Qian X; Cui J
Bioorg Med Chem; 2009 Jan; 17(2):804-10. PubMed ID: 19070496
[TBL] [Abstract][Full Text] [Related]
4. Bis-naphthalimides: a new class of antitumor agents.
Braña MF; Castellano JM; Morán M; Pérez de Vega MJ; Romerdahl CR; Qian XD; Bousquet P; Emling F; Schlick E; Keilhauer G
Anticancer Drug Des; 1993 Aug; 8(4):257-68. PubMed ID: 8240655
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs.
Hsiang YH; Jiang JB; Liu LF
Mol Pharmacol; 1989 Sep; 36(3):371-6. PubMed ID: 2550774
[TBL] [Abstract][Full Text] [Related]
6. The novel anti-tumor agents of 4-triazol-1,8-naphthalimides: synthesis, cytotoxicity, DNA intercalation and photocleavage.
Li X; Lin Y; Wang Q; Yuan Y; Zhang H; Qian X
Eur J Med Chem; 2011 Apr; 46(4):1274-9. PubMed ID: 21345546
[TBL] [Abstract][Full Text] [Related]
7. Novel thiazonaphthalimides as efficient antitumor and DNA photocleaving agents: effects of intercalation, side chains, and substituent groups.
Li Z; Yang Q; Qian X
Bioorg Med Chem; 2005 Aug; 13(16):4864-70. PubMed ID: 15925513
[TBL] [Abstract][Full Text] [Related]
8. New analogues of amonafide and elinafide, containing aromatic heterocycles: synthesis, antitumor activity, molecular modeling, and DNA binding properties.
Braña MF; Cacho M; García MA; de Pascual-Teresa B; Ramos A; Domínguez MT; Pozuelo JM; Abradelo C; Rey-Stolle MF; Yuste M; Báñez-Coronel M; Lacal JC
J Med Chem; 2004 Mar; 47(6):1391-9. PubMed ID: 14998328
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs.
Antonini I; Volpini R; Dal Ben D; Lambertucci C; Cristalli G
Bioorg Med Chem; 2008 Sep; 16(18):8440-6. PubMed ID: 18774722
[TBL] [Abstract][Full Text] [Related]
10. Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux.
Chau M; Christensen JL; Ajami AM; Capizzi RL
Leuk Res; 2008 Mar; 32(3):465-73. PubMed ID: 17826829
[TBL] [Abstract][Full Text] [Related]
11. Antitumor agents. 3. Design, synthesis, and biological evaluation of new pyridoisoquinolindione and dihydrothienoquinolindione derivatives with potent cytotoxic activity.
Bolognese A; Correale G; Manfra M; Lavecchia A; Mazzoni O; Novellino E; La Colla P; Sanna G; Loddo R
J Med Chem; 2004 Feb; 47(4):849-58. PubMed ID: 14761187
[TBL] [Abstract][Full Text] [Related]
12. R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II.
Zhu H; Huang M; Yang F; Chen Y; Miao ZH; Qian XH; Xu YF; Qin YX; Luo HB; Shen X; Geng MY; Cai YJ; Ding J
Mol Cancer Ther; 2007 Feb; 6(2):484-95. PubMed ID: 17308047
[TBL] [Abstract][Full Text] [Related]
13. A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis.
Chen Z; Liang X; Zhang H; Xie H; Liu J; Xu Y; Zhu W; Wang Y; Wang X; Tan S; Kuang D; Qian X
J Med Chem; 2010 Mar; 53(6):2589-600. PubMed ID: 20170164
[TBL] [Abstract][Full Text] [Related]
14. Methoxyethylamino-numonafide is an efficacious and minimally toxic amonafide derivative in murine models of human cancer.
Liu Y; Norton JT; Witschi MA; Xu Q; Lou G; Wang C; Appella DH; Chen Z; Huang S
Neoplasia; 2011 May; 13(5):453-60. PubMed ID: 21532886
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic and DNA binding properties of aminoalkyl derivatives of di- and triazaphenanthrenes.
Argiropoulos G; Bates MR; Cherubim P; Deady LW; Ganakas AM; Baguley BC; Denny WA
Anticancer Drug Des; 1992 Aug; 7(4):285-96. PubMed ID: 1510798
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of ethylnitrosoureas of substituted naphthalimides as anticancer compounds.
Pain A; Samanta S; Dutta S; Saxena AK; Shanmugavel M; Sharma M; Qazi GN; Sanyal U
Acta Pol Pharm; 2007; 64(1):27-33. PubMed ID: 17665847
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of amonafide dosing based on acetylator phenotype.
Ratain MJ; Mick R; Berezin F; Janisch L; Schilsky RL; Vogelzang NJ; Lane LB
Cancer Res; 1993 May; 53(10 Suppl):2304-8. PubMed ID: 8485716
[TBL] [Abstract][Full Text] [Related]
18. DNA binding and anticancer activity of naphthalimides with 4-hydroxyl-alkylamine side chains at different lengths.
Wang K; Wang Y; Yan X; Chen H; Ma G; Zhang P; Li J; Li X; Zhang J
Bioorg Med Chem Lett; 2012 Jan; 22(2):937-41. PubMed ID: 22200595
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties of novel indeno[2,1-c]quinolin-7-one and indeno[1,2-c]isoquinolin-5,11-dione derivatives.
Ryckebusch A; Garcin D; Lansiaux A; Goossens JF; Baldeyrou B; Houssin R; Bailly C; Hénichart JP
J Med Chem; 2008 Jun; 51(12):3617-29. PubMed ID: 18507368
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans.
Felder TB; McLean MA; Vestal ML; Lu K; Farquhar D; Legha SS; Shah R; Newman RA
Drug Metab Dispos; 1987; 15(6):773-8. PubMed ID: 2893701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
